United Therapeutics (UTHR) Liabilities and Shareholders Equity (2009 - 2026)

United Therapeutics has reported Liabilities and Shareholders Equity for 18 years, with the latest figure at $6.7 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 13.3% year-over-year to $6.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.9 billion (up 36.73% YoY) and the FY2025 annual result came in at $7.9 billion, up 7.01% from the prior year.
• Liabilities and Shareholders Equity slipped to $6.7 billion in Q1 2026 per UTHR's latest filing, from $7.9 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $7.9 billion in Q2 2025 and troughed at $2.6 million in Q3 2024.
• A 5-year average of $6.4 billion and a median of $6.7 billion in 2026 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity plunged 99.96% in 2024, then jumped 282634.62% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $6.0 billion in 2022, then rose by 18.57% to $7.2 billion in 2023, then climbed by 2.75% to $7.4 billion in 2024, then rose by 7.01% to $7.9 billion in 2025, then declined by 14.79% to $6.7 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $6.7 billion, $7.9 billion, and $7.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.